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The hydromethylglutaryl coenzyme A (HMG CoA) reduc-
tase inhibitors, “statins,” have been remarkably effective in
reducing low-density lipoprotein (LDL) cholesterol con-
centration, decreasing the incidence of coronary heart dis-
ease (CHD) and stroke, and extending survival (1–5).
Statins inhibit the synthesis of cholesterol primarily in the
liver. The hepatocyte, as its content of cholesterol decreases,
responds in two ways: it decreases the production of very
low-density lipoprotein (VLDL), the atherogenic precursor
of LDL, and increases the production of LDL receptors
that take up VLDL and LDL from plasma. These actions
substantially lower the VLDL and LDL concentrations in
plasma. The statin class reduces LDL cholesterol 30% to
55% from starting to maximal doses.
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Inhibitors of sterol absorption. The liver’s exquisite sen-
sitivity to a reduction in its content of cholesterol can be
exploited further for additional therapeutic benefit in pa-
tients who are being treated with statins. Reducing choles-
terol or bile acid absorption by the intestine has a down-
stream effect of reducing hepatocyte cholesterol, and is a
time-tested means of lowering plasma LDL concentration.
It is an important fact that agents that block intestinal sterol
absorption lower LDL concentration just as much if they
are taken with or without statins. This additivity provides
the opportunity to lower LDL cholesterol concentration
more than can be accomplished by statins alone. However,
this approach has had limited clinical success because of
mild efficacy, inconvenient administration, or side effects.
Bile acid sequestering resins, cholestyramine and colestipol,
have potential for 25% to 35% lowering of LDL cholesterol
at the highest dose (6), which is rarely reached because of
their gastrointestinal side effects, the need to dissolve the
resin in a beverage, and unpleasant texture and taste. For
these reasons, these resins are uncommonly prescribed, and
adherence to even a low dose is generally unsatisfactory.
Plant sterols and stanols, themselves nonabsorbable, reduce
intestinal cholesterol absorption and lower LDL cholesterol
by about 10% to 15% (7). Their clinical effectiveness is
limited by the requirement to eat special supplemented
foods, such as margarine 20 to 30 g daily. Dietary soluble
fiber reduces sterol absorption, which may account for some
of its modest action to lower LDL cholesterol, about 2
mg/dl per g soluble fiber (8). A synthetic soluble fiber,
colesevelam (WelChol, Sankyo Pharma, Piscattaway, New
Jersey), has recently been marketed in a tablet. Colesevelam,
a hydrophilic gel, is well tolerated and reduces LDL
cholesterol by 10% to 16% for 3.8 g (9,10), double or triple
the potency of natural dietary fiber (8). The advantages of
colesevelam are that it is not absorbed from the intestine
and the incidence of side effects is similar to placebo. One
would expect it to be as safe as fiber in food. The principal
drawback to treatment with colesevelam is that six tablets
per day taken with meals are needed to achieve the 3.8 g
daily dose. Thus, a truly convenient LDL-lowering therapy
with an intestinal mechanism of action has not been
available.
Ezetimibe: mechanism and efficacy. Into this therapeutic
gap enters ezetimibe (Zetia, Merck Schering Plough, North
Wales, Pennsylvania), an inhibitor of intestinal absorption
of cholesterol (11–16). Ezetimibe reduced cholesterol ab-
sorption from 50% to 23%, and among individuals the
reductions in cholesterol absorption and plasma LDL were
correlated (16). The well-conducted trial of Davidson et al.
(12) in this issue of the Journal demonstrates that a 10 mg
single daily dose lowers LDL cholesterol by 14%, in
addition to the effects of simvastatin. The study population
had moderately elevated LDL cholesterol averaging 180
mg/dl before treatment. Ezetimibe produced similar addi-
tional LDL reduction throughout the simvastatin dose
range, 10 to 80 mg. In patients with homozygous familial
hypercholesterolemia, a notoriously difficult condition to
treat pharmacologically, ezetimibe added a 20% LDL re-
duction to the effects of simvastatin or atorvastatin (13).
Pharmacologically, ezetimibe is truly a novel agent. Unlike
previous LDL-lowering agents with an intestinal action that
are not absorbed, ezetimibe is rapidly absorbed by the
intestinal cell, extensively glucuronidated, and produces
systemic concentrations of unmodified and glucuronidated
forms (14,15). Ezetimibe recirculates enterohepatically sev-
eral times a day in coordination with meals. The systemic
concentration of ezetimibe at any given dose varies consid-
erably among patients, fluctuates throughout the day, and is
directly related to the extent of LDL reduction (15).
Systemic trough levels of ezetimibe over 15 ng/ml were
found to produce consistent LDL lowering, and this was
achieved in most people with a single 10 mg daily dose. The
site of action is thought to be inside the enterocyte and not
in the intestinal lumen like all other agents that block
intestinal absorption of sterols. The mechanism by which
ezetimibe decreases cholesterol absorption is unknown.
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Ezetimibe has little effect on high-density lipoprotein
(HDL) cholesterol and triglycerides. Ezetimibe did not
produce adverse effects in combination with statin therapy,
and has minimal potential for interactions with other drugs.
Ezetimibe was approved by the Food and Drug Admin-
istration on October 25, 2002. The key question for
clinicians is how ezetimibe should be incorporated into
current practice to prevent and treat cardiovascular disease
(CVD).
Statins for first-line LDL treatment. Ezetimibe has little
potential as a first-line treatment for hyperlipidemia, as it
cannot compete with the clinical efficacy of statins on LDL
and CVD. There are over 50,000 patients who have
participated in placebo-controlled trials of five years or more
in duration, using pravastatin 40 mg, simvastatin 20 to 40
mg, or lovastatin 20 to 40 mg. All-cause mortality (1,2,4)
and virtually all cardiovascular events (1–5) are reduced.
Extended follow-up of two trials, Scandinavian Simvastatin
Survival Study (4S) (17) and Long-term Intervention with
Pravastatin in Ischemic Disease (LIPID) (18), showed that
the survival benefit persisted and even increased over two
years in the groups that had been randomized to active drug.
In the pravastatin (19) and simvastatin (4) trials, no increase
in liver transaminases occurred over that found with pla-
cebo, even in patients with elevated transaminase concen-
trations before treatment. There was no statistically signif-
icant increase in myalgia, myositis, myopathy, or high serum
creatine phosphokinase level with either drug. There was no
excess risk of myopathy with pravastatin 40 mg (19), and
with simvastatin 40 mg it was minuscule and not statistically
significant: six to seven cases per 10,000 treated patients in
five years, and no case was fatal (4).
These megatrials of pravastatin and simvastatin also
vanquished all the old shibboleths of lipid treatment related
to safety (20,21). There was no increase in any cause of
morbidity or mortality, most importantly cancer, to counter
the CVD benefits. In fact, on extended follow-up of the
LIPID and 4S trials, cancer rates were lower in the
pravastatin and simvastatin groups, with statistical signifi-
cance nearly achieved (17,18). Furthermore, in a random-
ized trial of patients with hepatocellular carcinoma, prava-
statin 40 mg significantly improved median survival (22).
Inhibition of HMG CoA reductase could suppress tumor
growth by reducing farnesyl isoprenoid formation, which
affects signal transduction by oncogene products. These
observations on cancer are particularly important, because
once initiated, lipid treatment needs to be given for decades
if not lifelong, and cancer incidence markedly increases with
age.
Now we will consider specific clinical situations. In a
typical population with CHD or other high-risk conditions
and with mean LDL cholesterol between 130 and 150
mg/dl, a starting dose of a statin would achieve the LDL
cholesterol goal of 100 mg/dl in the majority of patients,
and increasing to the next dose should suffice to bring most
of the other patients to this level. Flat pricing above starting
doses for some of the statins, such as pravastatin and
simvastatin, makes this approach economically attractive.
What to do when the LDL goal is not reached? Let us
now proceed to a more challenging patient with CVD who
has hypercholesterolemia, for example, with LDL choles-
terol before treatment of 190 mg/dl, the average pretreat-
ment level in the 4S trial (1). An initial dose of a statin
would lower LDL to about 125 mg/dl (34% from baseline).
Let us evaluate the risk reduction at this point and after
additional lipid therapies. The statin trials in the aggregate
suggest that relative risk reduction of 25% is achieved by a
40 mg/dl decrease in LDL cholesterol (1–4). Thus, a 40%
reduction in risk would be expected for this patient, consis-
tent with the actual results of 4S trial (1). Each doubling of
a statin dose reduces LDL cholesterol by about 6% (23). As
an example, increasing simvastatin from 20 to 80 mg would
lower LDL by another 12% (15 mg/dl), and this projects to
an additional 10% reduction in CHD. The result with the
ezetimibe strategy would be similar: a 14% reduction in
LDL cholesterol (12) and a projected 11% reduction in
CHD. It is clear that both strategies together would have to
be employed to reach the LDL goal 100 mg/dl, and this
would achieve about a 20% additional reduction in CHD
risk beyond the initial 40% reduction. Another option is to
add niacin 1.5 g daily, which will reduce LDL by 10% to
15%; HDL increasing with niacin is an added benefit in
patients with low HDL accompanying high LDL (24).
Perhaps the simplest option is to switch to atorvastatin 80
mg, which would produce a 53% to 56% reduction in LDL,
easily achieving the goal, although the potential for adverse
effects increases slightly (25,26), as discussed subsequently.
The first lesson from this exercise is that, after the initial
risk reduction from a starting dose of a statin, tinkering with
statin dose increases of one or two doublings or adding
ezetimibe or other inhibitor of intestinal sterol absorption
would be expected to produce rather modest effects on
CHD. These effects are also just projections; proof that high
doses of statins produce meaningful added reduction in
CHD awaits the results of several large trials that compare
simvastatin 80 mg with 20 mg (Study of the Effectiveness of
Additional Reductions in Cholesterol and Homocysteine
[SEARCH]) (27), atorvastatin 80 mg with 10 mg (Treating
to New Targets [TNT]), atorvastatin 80 mg with simvasta-
tin 20 to 40 mg (Incremental Decrease in End points
through Aggressive Lipid-lowering [IDEAL]), and atorva-
statin 80 mg with pravastatin 40 mg (Pravastatin or Ator-
vastatin Evaluation and Infection Therapy [PROVE-IT])
(28). Thus, exercising any of these options for additional
LDL therapy beyond pravastastin 40 mg (2), simvastatin 40
mg (1,4), and lovastatin 40 mg (3) takes us outside the
reassuring envelope of evidence-based medicine. Two dis-
tinct perspectives for adhering to such principles and essen-
tially to “leave well enough alone” pharmacologically have
been advanced recently in this Journal (29) and elsewhere
(30).
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Safety and the balance between benefit and harm. Although
efficacy of intensifying LDL lowering treatment eventually
may be borne out, safety and the balance between benefit
and harm is less easy to parse at this time. Adverse effects of
statin therapy are dose-dependent and have occurred in
trials primarily at the highest dose. For example, atorvasta-
tin 80 mg increased the incidence of serum transaminase
abnormalities during 16 weeks to 2.5% (38/1,538) com-
pared with 0.6% (9/1,548) on placebo (26). Two of the
patients were hospitalized for jaundice, which resolved. In a
study that compared atorvastatin 80 mg with simvastatin 80
mg in 826 patients for 30 weeks, atorvastatin was associated
with a higher incidence of serum transaminase abnormali-
ties (3.8% vs. 0.5%), including four cases with hyperbiliru-
binemia, and of gastrointestinal symptoms (10% vs. 3%)
(31). No cases of myopathy were reported for either drug
(31). In another trial of simvastatin 80 mg, there were two
cases of myopathy among 314 patients during 24 weeks; a
link to the drug was confirmed by the finding of high serum
simvastatin concentrations, 5- and 10-fold more than ex-
pected (32). In a pooled analysis of four controlled trials
comparing simvastatin 80 mg and 40 mg, confirmed
transaminase increases occurred in 1.5% (23/1,586) with 80
mg compared to 0.7% (4/543) with 40 mg, and myopathy in
0.6% (9/1,586) with 80 mg and 0.2% (1/543) with 40 mg
(33). The differences between doses were not statistically
significant. Lovastatin 80 mg was associated with an in-
creased incidence of high serum transaminase and creatine
kinase (34). The hepatic and muscular abnormalities re-
ported for the 80 mg dose of atorvastatin, simvastatin, and
lovastatin all were in excess of what occurred with lower
doses (32–35). Although these rates of adverse events are
low, we need to keep in mind that the 80-mg doses have
been evaluated only in short-term trials of 4 to 11 months
duration. The long-term safety is undetermined, pending
results from the large-scale longer-term studies in progress.
Thus, using these highest approved doses of statins requires
added caution. The recent American College of Cardiology/
American Heart Association/National Heart, Lung, and
Blood Institute clinical advisory on statin use (36) describes
clinical settings in which closer monitoring may be prudent,
such as in patients who are taking medications that increase
the serum concentration of certain statins, elderly or frail
patients, and those with multisystem disease.
Ezetimibe or statin dose escalation? Thus, with concerns
about high doses of statins, is ezetimibe a more attractive
option? Low-density lipoprotein lowering is modest but
reliable, the drug is conveniently taken, and no important
adverse effects or drug-drug interactions have come to light.
Nonetheless, several caveats are in order. First, the number
of patients who have been treated with ezetimibe is many
fewer than with high-dose statins. Second, the duration of
ezetimibe treatment in reported studies has been but 12
weeks (11–13). Third, the drug is absorbed and produces
serum concentrations that are related to its LDL lowering
effect (14,15). Finally, a “wild card” is that the molecular
action of ezetimibe is unknown. We do not know whether
the molecular target of ezetimibe is expressed in vivo in
tissues outside the intestine, and what the clinical effect
might be of interaction with ezetimibe. This could be
meaningful because systemic concentrations of ezetimibe
are maintained continually during therapy. For these rea-
sons, ezetimibe, the first of its class, needs careful scrutiny
after it is made available. Thus, to reach the goal for LDL,
I judge statin dose escalation to be the preferred option at
this time because the adverse effects are uncommon, well
known, and amenable to monitoring (36), and I would
reserve ezetimibe for patients who experience true adverse
effects from high-dose statins. Finally, we must persistently
reinforce and intensify nutrition and other therapeutic
lifestyle changes which have substantial, largely unrealized
potential to prevent CVD, diabetes, and other chronic
diseases.
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